Why do so many phase III trials fail

Of all drugs that enter clinical development, 4 in 5 fail to get approved, and half of the failures occur in phase 3.
Join the IDDI’s experts in this webinar and learn on statistical explanations for a large proportion of Phase III clinical trials failures, and how to address both the overestimation of treatment effects, and the misinterpretation of P-values via Bayesian methods.
More info on www.IDDI.com
Contact us at [email protected]

IDDI is an expert clinical data services and high-level strategic consulting contract research organization (CRO), providing agile clinical trials services for pharmaceutical, biotech, and medical device/diagnostic companies.
With a proven track record, IDDI provides expert Biostatistics and eClinical Services to ensure the successful execution of your clinical development program.